Market Overview

Barclays Increases Pfizer Price Target

Related PFE
Why GE's Removal From The Dow Could Help Investors
Deciphera Pharma Hit With Sell-Side Downgrade On Valuation After 50% Gain
Small-Cap Biotechs Developing Novel Gene Therapies Could Become Targets of Big Pharma (GuruFocus)

In a report released Wednesday, Barclays analyst Mark Purcell increases his price target for Pfizer (NYSE: PFE) from $32 to $34 per share, maintaining an Equal-Weight rating.

Analyst at Barclays are more bullish on the pharmaceutical sector, favoring Pfizer's potential for organic growth. Purcell mentions Pfizer's near-term potential depends on the company's ability to change its tax structure, increase transactions through core operations and increase its pipeline to full potential.

Shares of Pfizer are up about one percent.

Latest Ratings for PFE

May 2018BMO CapitalMaintainsOutperformOutperform
Apr 2018BarclaysDowngradesOverweightEqual-Weight
Jan 2018BarclaysMaintainsOverweightOverweight

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: Barclays Mark PurcellPrice Target Analyst Ratings


Related Articles (PFE)

View Comments and Join the Discussion!